NCT01552005View on ClinicalTrials.gov

Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France

CompletedOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Type 2 Diabetes Mellitus (T2D)
Interventions
DRUG

Saxagliptin

No Intervention

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY